Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC has announced that as of April 30, 2024, their issued share capital consists of 396,391,773 ordinary shares, each with one voting right, and confirms that shareholders may use this count as the basis for reporting changes in company interest. The company, known for developing a blood test for early lung cancer detection, does not hold any shares in Treasury, solidifying the total number of shares and voting rights. Their groundbreaking technology is based on detecting a variant of CIZ1 protein, which is indicative of early-stage lung cancer.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
